PhRMA Shifts Drug-Price Defense From R&D Cost To Health-System Value

The brand drug industry is pivoting from justifying drug prices based on research and development costs to justifying them based on the product's value to the health care system, a move that comes as key lawmakers, health plans and large employers -- upset by rising drug prices -- urge drug makers to disclose their research spending and their rationale for prices. The drug-price debate laid dormant for years before Gilead Sciences brought it back by charging $84,000 per regimen for...